BioPorto A/S
BIOPOR
Rang in Aktien
#22972
BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker... BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations. Additionally, BioPorto produces enzyme-linked immunosorbent assay (ELISA) kits and a versatile rapid assay device tailored for custom lateral flow assay development. Established in 1917, the company is headquartered in Hellerup, Denmark.
Aktienkurs
$0.15400149
Marktkapitalisierung
$76.25M
Veränderung (1 Tag)
-5.83%
Veränderung (1 Jahr)
-46.53%
Land
DK
Handel BioPorto A/S (BIOPOR)
Kategorie
Healthcare
Kursverlauf für BioPorto A/S (BIOPOR)
Höchster Schlusskurs: $0.15 am 2026-10-01
Niedrigster Schlusskurs: $0.41 am 2019-12-01
Niedrigster Schlusskurs: $0.41 am 2019-12-01
Kursverlauf der Aktie von BioPorto A/S von 2019 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -35.32% |
| 2025 | 0.00% |
| 2024 | -28.16% |
| 2023 | -37.74% |
| 2022 | -14.14% |
| 2021 | 106.94% |
| 2020 | -11.60% |
| 2019 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $694.53 | 24.47% |
US
|
|
| $234.00 | 5.99% |
US
|
|
| $416.01 | 122.61% |
US
|
|
| $22.06 | 54.01% |
CN
|
|
| $177.93 | 22.13% |
US
|
